Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

NCT01498328 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01498328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01498328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
May 17, 2016
Enrollment
127 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell glioblastoma, glioblastoma, glioblastoma with oligodendroglial component, gliosarcoma, recurrent glioblastoma, relapsed glioblastoma, small cell glioblastoma